Prognostication and response assessment in liver and pancreatic tumors: The new imaging

Table 3 Data derived from the main published studies that have evaluated apparent diffusion coefficient values before and after trans-arterial treatments of primary and metastatic liver tumors

Study	n	b values (s/mm2)	ADC before treatment(× 10-3 mm2/s)	ADC after treatment(× 10-3 mm2/s)	Histotype	Treatment
Kamel et al[86]	38	0, 500	1.51	1.70	HCC	TACE
Sahin et al[87]	74	0, 50, 400, 800	1.10	1.27	HCC	TACE
Kamel et al[88]	24	0, 50, 750	1.86	2.13	HCC	TACE
Chen et al[89]	20	0, 500	1.56	2.09	HCC	TACE
Yuan et al[90]	41	0, 500	2.22	1.42	HCC	TACE
Deng et al[98]	6	0, 500	1.30	2.23	HCC	TARE
Kamel et al[99]	13	0, 500	1.65	1.95	HCC	TARE
Rhee et al[100]	20	0, 500	1.64	1.82	HCC	TARE
Mannelli et al[102]	36	0, 50, 500	1.64	1.92	HCC	TACE
Kubota et al[103]	25	0, 500	1.271	1.3571/1.2222	HCC	TACE
Liapi et al[120]	26	0, 500	1.51	1.79	Metastases (PanNET)	TACE
Li et al[121]	26	0, 750	1.31	1.59	Metastases (PanNET)	TACE

¹No disease relapse;

²Disease relapse. ADC values are presented as means. n: Number of patients; ADC: Apparent diffusion coefficient; HCC: Hepatocellular carcinoma; PanNET: Pancreatic neuroendocrine tumor; TACE: Trans-arterial chemoembolization; TARE: Trans-arterial radioembolization.